Moxonidine - Hypertension
You are here : Home > Formulary Search > Moxonidine - Hypertension
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
ASPH restrict use to cardiology only.
Documentation
PAD Profile
ChemicalSubstance :
Moxonidine
Indication :
Hypertension
Group Name :
Keywords :
Brand Names Include :
Physiotens
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Moxonidine is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Hypertension.
- Aliskiren
- Amlodipine
- Atenolol
- Azilsartan medoxomil
- Bendroflumethiazide
- Bisoprolol fumarate
- Candesartan cilexetil
- Captopril
- Carvedilol
- Celiprolol hydrochloride
- Chlortalidone
- Clonidine hydrochloride
- Co-tenidone (Atenolol/chlortalidone)
- Diltiazem hydrochloride
- Doxazosin mesilate
- Enalapril maleate
- Eprosartan
- Hydralazine hydrochloride
- Indapamide
- Irbesartan
- Irbesartan / Hydrochlorothiazide
- Lercanidipine hydrochloride
- Lisinopril
- Lisinopril / Hydrochlorothiazide
- Losartan potassium
- Metolazone
- Metoprolol tartrate
- Nebivolol
- Nicardipine hydrochloride
- Nifedipine
- Olmesartan medoxomil
- Perindopril arginine
- Perindopril erbumine
- Prazosin hydrochloride
- Propranolol hydrochloride
- Quinapril hydrochloride
- Ramipril
- Spironolactone
- Telmisartan
- Valsartan
- Valsartan with hydrochlorothiazide
Committee Recommendations (1)
GENERIC moxonidine has been considered by the PCN and has been assigned a GREEN traffic light status.
NOTE - the branded product, Physiotens, was considered BLACK at the PCN in May 2017.
NOTE - the branded product, Physiotens, was considered BLACK at the PCN in May 2017.